Zhong Nong Yuan Fang Holdings Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Zhong Nong Yuan Fang Holdings's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2001 |
Recent past performance updates
No updates
Recent updates
No updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Zhong Nong Yuan Fang Holdings has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How Zhong Nong Yuan Fang Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 01 | 0 | 0 | 0 | 0 |
Quality Earnings: Insufficient data to determine if ANAS has high quality earnings.
Growing Profit Margin: Insufficient data to determine if ANAS's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ANAS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare ANAS's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if ANAS's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: ANAS has a negative Return on Equity (0%), as it is currently unprofitable.